Genenta Science S.p.A. (GNTA)

NASDAQ: GNTA · IEX Real-Time Price · USD
3.340
+0.240 (7.74%)
At close: Jun 24, 2024, 11:03 AM
3.300
-0.040 (-1.20%)
After-hours: Jun 24, 2024, 4:00 PM EDT
7.74%
Market Cap 60.84M
Revenue (ttm) n/a
Net Income (ttm) -12.94M
Shares Out 18.22M
EPS (ttm) -0.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,879
Open 3.290
Previous Close 3.100
Day's Range 3.270 - 3.430
52-Week Range 2.200 - 6.390
Beta 0.77
Analysts Strong Buy
Price Target 20.00 (+498.8%)
Earnings Date May 5, 2023

About GNTA

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it d... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 15, 2021
Employees 14
Stock Exchange NASDAQ
Ticker Symbol GNTA
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for GNTA stock is "Strong Buy." The 12-month stock price forecast is $20.0, which is an increase of 498.80% from the latest price.

Price Target
$20.0
(498.80% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Genenta Welcomes New Directors John L. Cantello, Lauren H.

MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoie...

7 weeks ago - GlobeNewsWire

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

Based on Preliminary Data from Ongoing Dose Ranging Stage of the Phase 1/2 Clinical Trial Based on Preliminary Data from Ongoing Dose Ranging Stage of the Phase 1/2 Clinical Trial

4 months ago - GlobeNewsWire

Genenta to Present at Upcoming Scientific and Investor Conferences

MILAN, Italy and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of he...

10 months ago - GlobeNewsWire

Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Canc...

11 months ago - GlobeNewsWire

The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma

MILAN, Italy and NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoi...

1 year ago - GlobeNewsWire

Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing

MILAN, Italy and NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of he...

1 year ago - GlobeNewsWire

Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications

MILAN, Italy and NEW YORK, April 03, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopo...

1 year ago - GlobeNewsWire

FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme

MILAN and NEW YORK, March 02, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic s...

1 year ago - GlobeNewsWire

Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement

MILAN, N.Y., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company engaged in the development of hematopoietic stem progenitor cell immuno-gene thera...

1 year ago - GlobeNewsWire

Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients

• Signs of intra-tumor pro-inflammatory state in patients• Temferon™ induced immune system reset in preclinical studies• Macrophage and T cell profiles in patients' tumor microenvironment echo preclin...

1 year ago - GlobeNewsWire

Genenta Provides First Half 2022 Business Update and Financial Results

MILAN, Italy and NEW YORK, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), (“Genenta” or the “Company”), a clinical stage immuno-oncology company developing a cell-based platform har...

1 year ago - GlobeNewsWire

Genenta to Present at Upcoming Investor Conferences

MILAN, Italy and NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopo...

1 year ago - GlobeNewsWire

AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative

Think tank of Italian companies and entrepreneurs listed or to be listed on US capital markets Think tank of Italian companies and entrepreneurs listed or to be listed on US capital markets

2 years ago - GlobeNewsWire

Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA

MILAN, Italy and NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immu...

2 years ago - GlobeNewsWire

Genenta Appoints Industry Veteran Tim Obara as Head of Business Development

Extensive experience in business development with AstraZeneca and GSK Extensive experience in business development with AstraZeneca and GSK

2 years ago - GlobeNewsWire

Genenta Files Annual Report on Form 20-F for Fiscal Year 2021

MILAN, Italy and NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor ce...

2 years ago - GlobeNewsWire

Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme

No dose limiting toxicity observed in previous three dose level cohortsRepresents a 50% higher dose than highest prior levelUpdate of guidance for trial

2 years ago - GlobeNewsWire

Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in Glioblastoma

Initial evidence of potential to modulate tumor microenvironment Initial evidence of potential to modulate tumor microenvironment

2 years ago - GlobeNewsWire

Genenta Announces Nomination of Mark A. Sirgo as Chair

35 years industry experience including as CEO and founder of public company

2 years ago - GlobeNewsWire

Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors

*** David Reardon, Luigi Naldini, Brad Loncar *** *** David Reardon, Luigi Naldini, Brad Loncar ***

2 years ago - GlobeNewsWire

Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma Multiforme

Data to be presented at the 2022 annual meeting of American Association for Cancer Research Data to be presented at the 2022 annual meeting of American Association for Cancer Research

2 years ago - GlobeNewsWire

Genenta to Participate at Upcoming Investor Conferences

MILAN, Italy and NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell imm...

2 years ago - GlobeNewsWire

Genenta Closes Its Upsized Initial Public Offering of American Depository Shares

MILAN, Italy and NEW YORK, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor c...

2 years ago - GlobeNewsWire

Genenta Announces Pricing of Upsized Initial Public Offering

MILAN, Italy and NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Genenta Science S.p.A., a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene...

2 years ago - GlobeNewsWire